



The Future of Neurocare: Your Eyes, Your Story, Our Expertise.

CONTACT INFORMATION:

Founder, CEO: Rachel Kuperman, MD
rkuperman@eyszlab.com

STAGE:

Software released as FDA Class 1 SaMD
Early Adopter Program Launched: 1 contract signed
Initial Indication: Childhood Absence Epilepsy

FUNDING SOUGHT:

\$4M Seed Round
Use of Proceeds: R&D, Product Launch, Regulatory, Clinical Studies
Prior Funding: \$4.3M (Investors: UCB Pharma, Sandhills Angels, Plug N Play Ventures; National Science Foundation, National Institutes of Health)

ADDRESSABLE MARKETS:

Initial market will be Provider market for Epilepsy (\$1.1B). We will then expand into other Provider markets - ADD/ADHD (\$1.7B) and Depression (\$2.7B). SaaS based business model.

COMPANY:

Founded in 2018; Headquartered in California
5 Employees
Extensive Patent Portfolio

MANAGEMENT TEAM / ADVISORY BOARD:

- CEO: Rachel Kuperman, MD – 10+ years
Director UCSF Benioff Children’s Hospital
Epilepsy Center
- COO: Parth Amin, – 20+ years Med Device
- CTO: Jit Sarkar, PhD – 15+ years AI/ML software
development
- Advisors: Robert Fisher, MD/PhD, Stanford;
Peter Milford, PhD, Previously Google,
Eyefluence

EXECUTIVE SUMMARY

Eysz is developing a cutting-edge digital health platform that analyzes eye and facial movements to measure consciousness, cognition, and mood. This enables clinicians to rapidly diagnose and manage a wide range of neurological diseases, starting with Epilepsy which affects millions worldwide and annual costs exceeding \$50 billion in the USA and Europe alone. Currently, the standard of care for epilepsy management heavily relies on unreliable patient-reported data. This results in diagnostic delays, long-treatment cycles, and ineffective new therapies. Additionally, people with epilepsy have comorbidities of attention and depression. Our digital health platform will provide doctors with the objective biomarker they need to accelerate the path to diagnosis, measure comorbidities, and identify patients that are treatment resistant sooner. This will be measured through decreased time to seizure freedom, improved QOL and decreased costs. Towards this goal, Eysz completed a 168-patient multicenter clinical study funded showing that eye movements analysis can be used to identify absence seizures and cognitive changes associated with epilepsy. We initiated a limited release of our first product in Q4 2023 and are working with early adopters to prove value; also we are currently preparing for a post market clinical study.

MARKET AND COMPETITION

The Epilepsy Provider market valued at \$1.1 billion. Unlike our competitors in Epilepsy, our comprehensive digital health platform goes beyond seizure detection, addressing neurocognitive and mood symptoms, which will allow us to scale easily into other neurological disorders while providing value to Providers throughout the care continuum. Providers will be able to capture new revenue while providing better care which will improve outcomes for people living with epilepsy and their caregivers. Additionally, Eysz will work with Pharma to support their clinical trials.

STRATEGY AND EXIT

The goal of this current round is to launch our first product and develop our cognitive screening product. The next funding round will assist in commercialization of our second product and scaling to OUS. Eysz will drive the growth and value of our company through product sales, licensing of our data, and strategic partnerships.